Corteva, Inc.

Corteva, Inc. (CTVA) Market Cap

Corteva, Inc. has a market capitalization of —.

No quote data available.

CEO: Charles Magro

Sector: Basic Materials

Industry: Agricultural Inputs

IPO Date: 2019-05-24

Website: https://www.corteva.com

Corteva, Inc. (CTVA) - Company Information

Market Cap: -|Sector: Basic Materials

Company Profile

Corteva, Inc. operates in the agriculture business. The company operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics. This segment also provides digital solutions that assist farmer decision-making with a view to optimize product selection, and maximize yield and profitability. The Crop Protection segment offers products that protect against weeds, insects and other pests, and diseases, as well as enhances crop health above and below ground through nitrogen management and seed-applied technologies. This segment provides herbicides, insecticides, nitrogen stabilizers, and pasture and range management herbicides. It serves agricultural input industry. The company operates in the United States, Canada, Latin America, the Asia Pacific, Europe, the Middle East, and Africa. Corteva, Inc. was founded in 1802 and is headquartered in Indianapolis, Indiana.

Analyst Sentiment

76%
Strong Buy

From 23 Active Polls

1Y Forecast: $92.00

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$86

Median

$91

High Bound

$103

Average

$92

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$92.00
▲ +16.88% Upside
Low Target
$86.00
9% Risk
Median Target
$90.50
15% Mid
High Target
$103.00
31% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

valuation & financial ratiosdetailed financials

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CORTEVA INC (CTVA) — Investment Overview

🧩 Business Model Overview

Corteva supplies agricultural inputs that influence farm economics across two connected stages: (1) seed genetics (hybrid/traited seeds) and (2) crop protection (chemistry and biological solutions). The company sells to large and small growers through a blend of direct relationships and an extensive network of distributors/retail partners. Customers typically purchase for the planting cycle, then choose follow-on inputs based on agronomic performance, local disease/pest pressure, and agronomic fit with their crop rotation.

The “how it works” is largely a repeat purchase + performance feedback loop: farmers trial and adopt specific seed/trial packages, then maintain or adjust trait and chemistry choices based on yield outcomes and resistance management. Corteva monetizes its science through product sales (seed and crop protection) and through intellectual-property-linked economics (notably trait-related royalties and licensed genetics where applicable), while using scale manufacturing and formulation to support competitive unit economics.

💰 Revenue Streams & Monetisation Model

  • Seed sales (hybrid/traited): Transactional revenue tied to planting demand. Margin profile benefits from premium trait content, product mix, and effective inventory management around seasonal cycles.
  • Crop protection sales: Product revenue across herbicides, insecticides, fungicides, and related formulations. Profitability depends on efficacy, formulation/active ingredient sourcing costs, and product mix (including higher-value programs and stewardship-driven replacements).
  • Trait and technology economics: Ongoing economic participation from genetics/technology where licensed/royalty structures apply, providing a more structural component of monetisation versus purely seasonal product sales.

Margin drivers typically center on (i) the mix shift toward higher-value seed genetics and effective crop protection programs, (ii) R&D productivity translating into commercially differentiated products, and (iii) operating leverage enabled by scale in manufacturing, formulation, and logistics. Because agricultural inputs are efficacy- and performance-driven, successful product launches can support premium pricing and improved gross margin even when volume is volatile.

🧠 Competitive Advantages & Market Positioning

Corteva’s moat is best described as a combination of high switching costs (especially in seeds) and intellectual property (traits and crop protection platforms), reinforced by regulatory and agronomic know-how. Farmers do not switch seed genetics lightly because outcomes are observable only across the growing season and are affected by trait “fit” with local environments, pest/disease patterns, and crop management practices.

Primary competitive landscape (examples):

  • Bayer (notably crop protection and legacy genetics/trials)
  • Syngenta / Syngenta Crop Protection (broad crop protection and genetics presence)
  • BASF (crop protection scale and formulation capabilities)

Contrast vs. rivals:

  • Portfolio focus and integration: Corteva’s positioning emphasizes broad coverage across seeds + crop protection, which supports coordinated agronomic programs. While many competitors are strong in one segment, Corteva’s combination can improve cross-sell and program stickiness.
  • Trait-led seed differentiation: Compared with more chemistry-only exposures, Corteva’s seed/trial economics benefit from trait platforms that raise adoption friction for growers and competitors due to agronomic compatibility and performance history.
  • Regulatory and stewardship pathways: Crop protection remains highly regulated and effectiveness matters under resistance pressure. Competitors with comparable R&D depth can compete, but large-scale efficacy portfolios and stewardship programs tend to be harder to replicate quickly.

Moat summary: Corteva is advantaged by IP-protected traits, performance-based switching costs in seed adoption, and scale manufacturing and distribution that supports consistent delivery of differentiated programs.

🚀 Multi-Year Growth Drivers

  • Yield improvement and trait adoption: Structural demand for genetic improvements that enhance yield stability, stress tolerance, and pest resistance supports sustained replacement cycles in seed.
  • Rising intensity of crop protection programs: Higher-value crops, shifting pest/disease dynamics, and continued emphasis on residue and resistance management sustain demand for integrated protection solutions.
  • Emerging market expansion: Increased use of purchased inputs and modern agronomic practices in underpenetrated geographies expands the addressable market for both seeds and crop protection.
  • Stewardship and “replacements” after regulatory changes: When older active ingredients face restrictions, faster product replacement with proven efficacy can improve share capture and product mix.
  • Biologicals and formulation innovation: While competitive intensity exists, incremental platform improvements can shift a portion of the portfolio toward higher-value, defensible programs.

Across a 5–10 year horizon, the key theme is not only volume growth in agriculture, but value capture through agronomic differentiation—traits and protection programs that improve outcomes per hectare.

⚠ Risk Factors to Monitor

  • Regulatory and compliance risk: Changes in pesticide approvals, residue standards, and stewardship requirements can affect product economics and launch timelines.
  • Efficacy and resistance pressure: Resistance to crop protection modes of action can reduce product effectiveness, increasing the need for new chemistry and program redesign.
  • Patent/trait life-cycle risk: Trait and chemistry platform maturation can lead to periodic erosion, requiring sustained R&D success to maintain differentiation.
  • Seasonality and weather variability: Demand and timing depend on planting conditions and crop outcomes, which can introduce revenue volatility.
  • Commodity-price and farmer affordability dynamics: Farmer purchasing behavior can weaken when commodity prices fall, even for high-performance inputs.
  • Capital intensity and supply chain execution: Crop protection manufacturing and seed production require operational discipline; disruptions can impact service levels and gross margin.

📊 Valuation & Market View

Equity valuation for agricultural input companies typically reflects a blend of EV/EBITDA-style operating cash flow expectations and segment growth and margin quality. Market focus often centers on:

  • Gross margin sustainability: driven by product mix (premium traits and differentiated crop protection programs) and disciplined manufacturing/formulation costs.
  • R&D productivity: the pipeline conversion rate from discovery to commercial adoption.
  • Operating leverage: the ability to convert stable demand and mix improvements into margin expansion despite seasonality.
  • Resilience of seed economics: switching costs and repeat adoption that support more durable revenue quality than purely commodity-like inputs.

In institutional frameworks, the “multiple” is most sensitive to confidence in sustained differentiation (traits + protection efficacy), rather than to one-off planting-cycle outcomes.

🔍 Investment Takeaway

Corteva’s long-term investment case rests on a defensible position in agricultural outcomes through trait-led seed differentiation and integrated crop protection programs. The structural moat is reinforced by high switching costs for growers, intellectual property barriers, and the operational scale needed to deliver differentiated products under regulatory and resistance constraints. Over a multi-year horizon, growth is most likely to come from value capture—greater adoption of improved genetics and protection intensity—supported by continued R&D pipeline execution and stewardship-driven portfolio renewal.


⚠ AI-generated — informational only. Validate using filings before investing.

Related Companies in Basic Materials

STEEL DYNAMICS INC (STLD)

Basic Materials

$36.01B

Mkt Cap

DUPONT DE NEMOURS INC (DD)

Basic Materials

$18.50B

Mkt Cap

DOW INC (DOW)

Basic Materials

$21.88B

Mkt Cap

ALBEMARLE CORP (ALB)

Basic Materials

$13.87B

Mkt Cap

MARTIN MARIETTA MATERIALS INC (MLM)

Basic Materials

$31.53B

Mkt Cap

LYONDELLBASELL INDUSTRIES NV CLASS (LYB)

Basic Materials

$20.04B

Mkt Cap

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"CTVA reported Q2’26 revenue of $6.379B and net income of $1.161B (EPS $1.74). Versus Q2’25, revenue rose 0.0% (≈$6.379B vs. $6.456B), while net income increased 11.3% ($1.161B vs. $1.314B). On a QoQ basis, revenue jumped 30.1% (from $4.905B in Q1’26), and net income rose 61.1% (from $0.720B). Profitability improved sharply QoQ: operating margin expanded to 12.2% from 23.7% in Q1’26 (notably, the quarterly sequence shows large swings), but net margin improved to 18.2% from 14.7% QoQ. Importantly, after losses in Q3–Q4’25, the company returned to strong profitability in Q1’26 and sustained it in Q2’26 (net margin positive again). Cash flow quality weakened in Q2’26: operating cash flow was -$0.454B and free cash flow -$0.576B, driven by a large working-capital/other non-cash headwind. Still, the company maintained shareholder distributions: dividends paid were -$0.120B, while buybacks continued (-$0.250B). From a total shareholder return perspective, CTVA’s stock is up 35.7% over 1 year, indicating strong capital appreciation and supporting the outlook despite near-term cash flow volatility."

Revenue Growth

Neutral

QoQ revenue accelerated +30.1% to $6.38B, while YoY was roughly flat (~-1.2%). Trajectory improves sequentially but lacks YoY growth.

Profitability

Positive

Net income rose +61.1% QoQ and +11.3% YoY. Net margin improved QoQ to 18.2% from 14.7%, though margin levels remain volatile across the 4-quarter window (losses in late-2025).

Cash Flow Quality

Caution

Operating cash flow was -$0.45B and free cash flow -$0.58B in Q2’26, a deterioration vs Q1’26 and especially vs the positive cash generation in Q4’25. Distributions continued, but cash conversion in the quarter was poor.

Leverage & Balance Sheet

Positive

Balance sheet remains resilient: total assets were $41.6B and equity about $25.4B. Debt is manageable (total debt ~$4.9B; net debt ~$2.5B), with liquidity supported by $2.37B cash/short-term investments.

Shareholder Returns

Good

1-year price appreciation is strong (+35.7%). Q2’26 included dividends (-$0.12B) and continued buybacks (-$0.25B), supporting total return despite weaker cash flow.

Analyst Sentiment & Valuation

Neutral

Consensus target is $92 vs. current price $80.34 (implied upside ~14.6%). High momentum may be partly discounting execution, while cash flow volatility tempers conviction.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

RevenueEarningsP/E RatioSharesDebtMargin %

Fundamentals Overview

Loading fundamentals overview...

Corteva delivered strong 1H26 execution (net sales +4%, operating EBITDA +10%, operating EPS +14%) and raised full-year guidance. Management lifted operating EBITDA to $4.1B–$4.3B and EPS to $3.60–$3.80, with margin outlook increased to 22.5%–23.5%. The update is supported by seed technology adoption and especially licensing—now described as ~3 years ahead of original plan—and crop protection volume growth from new products, while pricing was essentially flat in 1H. The key macro/competitive tension is concentrated in Brazil: management expects CP pricing to decline low-to-mid single digits in 2H, despite a differentiated portfolio and improved cost structure. Separation is progressing on time and under budget toward October 1; reported separation headwind is modest (~$25M) and run-rate synergies have largely been offset. Q&A emphasized that 2H seed acres assumptions rely on Latin America (Brazil safrinha) rather than North America.

AI IconGrowth Catalysts

  • Seed genetics demand and continued adoption of latest genetics/trade offerings; strong organic growth across regions in 1H26
  • Licensing business growth (explicitly “growing contribution from our new licensing business”); seed licensing 3 years ahead of original plan
  • Crop protection new products delivering volume growth (high single digit growth in new products) while pricing was essentially flat in 1H26
  • Cost productivity initiatives and lower cost of production supporting margin expansion and earnings quality

Business Development

  • Separation on track toward October 1; Vylor named for the future advanced seed and genetics company
  • Asset expansion in nature-based crop protection via a recent acquisition (mentioned as expanding capabilities in nature based products)

AI IconFinancial Highlights

  • 1H26 net sales +4%; operating EBITDA +10%; operating EPS +14% (company-driven execution across seed and crop protection)
  • Q2 net sales $6.4B; operating EBITDA +4% to $2.3B
  • 1H26 margin expansion to 32.8% (nearly 200 bps margin expansion cited for the first half overall)
  • Full-year raise: operating EBITDA $4.1B–$4.3B (≈9% growth at midpoint vs prior year); operating EPS $3.60–$3.80 (≈11% growth at midpoint)
  • Operating EBITDA margin outlook raised to 22.5%–23.5%
  • 2H assumptions: Brazil corn area approximately flat; seed organic sales low single digit growth; crop protection volume high single digit growth with pricing down low-to-mid single digits
  • Currency benefit in 1H26: ~€-driven $85M benefit (during first half)
  • Net seed royalties: improved seed net royalties $90M in 1H26; expectation to be net royalty positive this year
  • Separation headwind: expect ~$25M headwind in 2026 due to timing of separation activities; separation IT activities and remaining Form 10 milestones ongoing
  • 2H EBITDA expected about flat YoY with tariffs/separation and Middle East conflict “weighted to the back half of the year”

AI IconCapital Funding

    AI IconStrategy & Ops

    • Maintaining separation execution while sustaining customer focus and performance; synergies largely offset on a run-rate basis
    • Asset optimization and productivity cost management as a recurring driver; cost performance largest contributor to 1H EBITDA bridge (+$160M+ lower input cost/manufacturing efficiencies/productivity initiatives)
    • Portfolio positioning: ~2/3 of current crop protection portfolio described as differentiated technology
    • Pricing strategy recalibrated in 2H: CP pricing move from low single digits down to low-to-mid single digits down (explicitly attributed to Brazil and limited pockets; not uniform)
    • Weather sensitivity: dry markets (Europe/US) expected to reduce fungicide demand relative to wetter conditions (El Nino referenced)

    AI IconMarket Outlook

    • Investor guidance (full-year): operating EBITDA $4.1B–$4.3B; operating EPS $3.60–$3.80; operating EBITDA margin 22.5%–23.5%
    • 2H operational expectations: Brazil corn area ~flat; seed low single digit organic sales growth; crop protection volumes high single digit growth; pricing down low-to-mid single digits
    • Seasonality: Q3 operating EBITDA loss expected in the range of 2024; all 2H earnings delivered in Q4
    • Separation timeline: Investor Day events September 15 (Vylor and Corteva) and target separation date October 1

    AI IconRisks & Headwinds

    • Competitive pricing pressure in crop protection pockets, especially Brazil; pricing decline low-to-mid single digits expected in 2H (Brazil not uniform)
    • Weather risk via El Nino (dry markets reduce fungicide application demand; noted for Europe and parts of US)
    • North/South hemisphere operational dependence: IIH depends on Brazil planted area dynamics (safrinha expansion typically low-single digit but may flatten)
    • Pricing pressure pockets and geopolitical/FX uncertainty remain monitored
    • Competitive tension risk from in-market molecules coming off patent; management cited anticipation of competitive tension but claims margin profile remains up via cost structure redesign

    Q&A: Analyst Interest

    • Topic: 2H seed assumptions—flat corn acres, Latin America/brazil planted area, order book strength, and Conkesta penetration trajectory. Management: maintained confidence; typical low-single-digit safrinha expansion or possible flattening; order book ahead of market; strong portfolio; Latin America pricing momentum; Conkesta E3 expected high-single to low-double-digit penetration in 2027 on plan.
    • Topic: Longer-term financial trajectory for New Corteva—relationship to prior 2027/target EBITDA and whether growth needs recalibration. Management: original thinking largely unchanged; updated 2026 guide supports 2027 framework; 4.2 fits within prior 2027 plan; growth slightly ahead of earlier plan; licensing 3 years ahead and new products supporting; net dis-synergies tracking near flat.
    • Topic: Crop protection differentiated portfolio vs observed pricing—how to reconcile low-single-digit pricing in 1H and move to low-to-mid single-digit in 2H with differentiation claims. Management: Europe and US essentially flat; “new products” ~high-single-digit volume with essentially flat prices approach ~$2B revenue; pricing declines mainly Brazil plus a few pockets; preemergent herbicides under pressure; fungicide demand reduced by dry El Nino weather.

    Sentiment: MIXED

    Note: This summary was synthesized by AI from the CTVA Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

    Loading financial data and tables...
    © 2026 Stock Market Info — Corteva, Inc. (CTVA) Financial Profile